Avid Bioservices, Inc.

$12.49+0.00%(+$0.00)
TickerSpark Score
51/100
Mixed
75
Valuation
20
Profitability
10
Growth
52
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDMO research report →

52-Week Range100% of range
Low $5.90
Current $12.49
High $12.51

Companywww.avidbio.com

Avid Bioservices, Inc. , a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.

CEO
Nicholas Stewart Green MBA
IPO
1994
Employees
371
HQ
Tustin, CA, US

Price Chart

+91.56% · this period
$12.49$9.29$6.09Feb 06Aug 07Feb 06

Valuation

Market Cap
$798.90M
P/E
-5.61
P/S
5.71
P/B
12.96
EV/EBITDA
-84.37
Div Yield
0.00%

Profitability

Gross Margin
5.23%
Op Margin
-13.35%
Net Margin
-100.60%
ROE
-112.44%
ROIC
-6.95%

Growth & Income

Revenue
$139.91M · -6.27%
Net Income
$-140,753,000 · -25234.46%
EPS
$-2.23 · -24877.78%
Op Income
$-18,678,000
FCF YoY
76.96%

Performance & Tape

52W High
$12.51
52W Low
$5.90
50D MA
$12.36
200D MA
$10.25
Beta
1.41
Avg Volume
1.58M

Get TickerSpark's AI analysis on CDMO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 5, 25Ziebell Mark Rsell14,286
Feb 5, 25Ziebell Mark Rsell21,429
Feb 5, 25Ziebell Mark Rsell1,733
Feb 5, 25Ziebell Mark Rsell98,120
Feb 5, 25Ziebell Mark Rsell17,679
Feb 5, 25Ziebell Mark Rsell51,413
Feb 5, 25Ziebell Mark Rsell55,310
Feb 5, 25Ziebell Mark Rsell108,579
Feb 5, 25Ziebell Mark Rsell66,799
Feb 5, 25Thoma Jeannesell45,611

Our CDMO Coverage

We haven't published any research on CDMO yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate CDMO Report →

Similar Companies